Active Filter(s):
Details:
The acquisition adds BrainVectis's Huntington’s disease drug candidate BV-CYP01 to AskBio’s program.
Lead Product(s): BV-CYP01
Therapeutic Area: Genetic Disease Product Name: Undisclosed
Highest Development Status: Preclinical Product Type: Cell and Gene therapy
Partner/Sponsor/Collaborator: AskBio
Deal Size: Undisclosed Upfront Cash: Undisclosed
Deal Type: Acquisition April 22, 2020